Key Decisions in HIV Care: Switching to Long-Acting ART
Listen as Daniel R. Kuritzkes, MD, explains key clinical trial data and gives practical insights such as how to initiate a patient on long-acting therapy, recommended dosing regimens, and factors that may increase the risk of treatment failure.
Decera Clinical Education Infectious Disease Podcast · Daniel J Kuritzkes MD
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, Daniel J. Kuritzkes, MD, reviews key clinical trial data and gives practical insights such as how to initiate a patient on long-acting therapy, recommended dosing regimens, and factors that may increase the risk of treatment failure. The overview will include analyses of:
- ATLAS and FLAIR studies of long-acting injectable CAB + RPV
- ATLAS 2M dosing study
- FDA approval and DHHS statement on use of long-acting injectable ART
- Studies on whether an oral lead-in is needed
Presenter:
Daniel R. Kuritzkes, MD
Chief, Division of Infectious Diseases
Brigham and Women’s Hospital
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Follow along with the slides at:
https://bit.ly/3hNfHII
See the entire program at:
https://bit.ly/2TXTYWx
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.